Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00192829
First received: September 13, 2005
Last updated: April 10, 2007
Last verified: March 2007

September 13, 2005
April 10, 2007
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00192829 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

Not Provided
Observational
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
  • Non-Small Cell Lung Carcinoma
  • Venous Thromboembolism
Procedure: Blood sample withdrawal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
Not Provided
Not Provided

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease
Both
Not Provided
No
Contact: Galit Sarig, Ph.D +972-4-8543503 g_sarig@rambam.health.gov.il
Contact: Nissim Haim, M.D
Israel
 
NCT00192829
Thrombosis and cancer.CTIL
Not Provided
Not Provided
Rambam Health Care Campus
Not Provided
Principal Investigator: Galit Sarig, Ph.D Rambam Health Care Campus
Rambam Health Care Campus
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP